- Company
- Adtralza becomes the 2nd reimbursed biological drug for AD
- by Son, Hyung-Min May 31, 2024 05:52am
- LEO Pharma Korea has launched Adtralza (tralokinumab) as the 2nd biologic drug in the atopic dermatitis market and is on its way to take on Dupixent. LEO Pharma has been emphasizing that Adtralza has a longer dosing interval after 16 weeks compared to existing therapies and is relatively cheaper, reducing the cost burden for patients.
- Company
- Delay after delay…When will Phesgo be reimb in Korea?
- by Eo, Yun-Ho May 31, 2024 05:51am
- The biobetter breast cancer treatment ‘Phesgo’ is facing a tough road to insurance coverage in Korea. Roche Korea’s subcutaneous fixed-dose combination injection Phesgo (pertuzumab, trastuzumab) that combined ‘Perjeta’ and ‘Herceptin’ has passed the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Commi
- Company
- Over 50,000 ppl signed 2nd petition for Trodelvy’s reimb
- by Eo, Yun-Ho May 30, 2024 05:50am
- The second petition calling for the insurance reimbursement of the breast cancer drug 'Troldelvy (sacituzumab govitecan-hziy)' has again garnered over 50,000 signatures. This is the second petition filed after the first in January that garnered 50,000 signatures. Patients are growing increasingly desperate, as 3 months have passed with li
- Company
- 11 years since global entry…K-biosimilars
- by Chon, Seung-Hyun May 29, 2024 05:45am
- The biosimilar products developed by Korean companies are actively tapping into the global market. Celltrion received approval for Remsima in Europe in 2013. Since then, Koran companies have successfully commercialized 15 products in Europe and 12 products in the United States for the past 11 years. Celltrion secured 11 approvals in Europe and t
- Company
- Six pharmaceutical companies challenge the 'Esgliteo' patent
- by Kim, Jin-Gu May 29, 2024 05:45am
- Generic companies have claimed patent challenges against Boehringer Ingelheim’s combination therapy for diabetes, 'Esgliteo (empagliflozin+linagliptin).' It is the strategy of six companies, including Boryung, to launch their generics early by avoiding or nullifying the patent of this combination therapy, which contains SGLT-2 inhibitor
- Company
- High-dose Eylea is approved in KOR
- by Son, Hyung-Min May 29, 2024 05:45am
- The higher-dose version of Eylea, which more than doubles the dosing interval, has been approved in Korea. With the approval, Eylea now owns the longest duration of effect among its competitors. Bayer held a press conference in Yeouido, Seoul, on the 28th to celebrate the approval of Eylea High Dose (8mg) in Korea. Eylea is a treatment fo
- Company
- 'Camzyos' anticipated for the DREC review consideration
- by Eo, Yun-Ho May 29, 2024 05:45am
- The industry is awaiting the progress on whether 'Camzyos,' the first novel drug for obstructive hypertrophic cardiomyopathy (oHCM), will receive an insurance reimbursement listing. According to industry sources, BMS Korea’s novel drug Camzyos (mavacamten) has cleared the review by the Economic Evaluation Committee of Health Insurance R
- Company
- Multinational pharmaceutical companies post mixed results
- by Son, Hyung-Min May 28, 2024 01:31pm
- The Korean subsidiaries of multinational pharmaceutical companies posted mixed performances last year. Sales of Pfizer Korea, MSD Korea, and Gilead Sciences Korea, which developed COVID-19 vaccines and treatments, plummeted due to the base effect of the pandemic. On the other hand, GlaxoSmithKline (GSK) and Amgen Korea saw sales increase thanks
- Company
- Handok strengthens global pharma partnerships
- by Kim, Jin-Gu May 28, 2024 05:52am
- Handok is strengthening its partnerships with global pharmaceutical companies. At the end of last year, Handok signed deals with the Dutch company Argenx and Swedish biopharmaceutical company Sobi for three rare disease treatments. This year, the company also launched a combination therapy for high blood pressure co-developed with Sanofi
- Company
- Roche’s Kadcyla sales KRW 70 bil…unrivaled lead in ADC mkt
- by Nho, Byung Chul May 28, 2024 05:52am
- Roche’s Kadcyla continues to remain the unrivaled lead in the domestic ADC (Antibody-Drug Conjugate) drug market, accounting for 60% share of the KRW 120 billion market. Based on drug distribution performance, the domestic ADC drug market was valued at KRW 113.8 billion last year, of which Kadcyla (treatment for HER2-positive metastati
